Searchable abstracts of presentations at key conferences in endocrinology

ea0041gp153 | Pituitary - Clinical | ECE2016

Once-monthly injection of pasireotide LAR reduces urinary free cortisol (UFC) levels in patients with Cushing’s disease: Results from a randomised, multicentre, phase III trial

Newell-Price John , Petersenn Stephan , Biller Beverly M K , Roughton Michael , Ravichandran Shoba , Lacroix Andre

Background: Twice-daily formulation of pasireotide, a pituitary-directed therapy, is approved for treatment of Cushing’s disease. Here we present data from a phase III study designed to evaluate the more convenient once-monthly long-acting release (LAR) formulation of pasireotide (approved for acromegaly) in patients with Cushing’s disease.Methods: Patients with persistent, recurrent, or de novo Cushing’s disease (not candidates for surger...

ea0037gp.01.02 | Adrenal | ECE2015

Defining and exploring the excessive healthcare burden of adrenal insufficiency

Stewart Paul , Biller Beverly M K , Marelli Claudio , Gunnarsson Candace , Ryan Michael , Johannsson Gudmundur

Introduction: The clinical outcome of patients with adrenal insufficiency (AI) has been shown to be less favorable than previously thought. Clinical studies have shown increased mortality, reduced cardiovascular and skeletal health and compromised quality of life, but the impact of this upon healthcare burden is unknown. This research utilised real-world evidence to compare comorbidities, healthcare utilization and expenditures in patients with AI.Method...

ea0049ep1015 | Pituitary - Clinical | ECE2017

Osilodrostat maintains normalized urinary free cortisol levels in a majority of patients with Cushing’s disease: Long-term results from an extension to the LINC-2 study

Young Jacques , Hatipogulu Betul , Molitch Mark E , Bertagna Xavier , Barbier Nathalie , Sauter Nicholas , Biller Beverly M K , Pivonello Rosario

Background: In the 22-week LINC-2 study, osilodrostat (LCI699), a potent oral 11β-hydroxylase inhibitor, normalized urinary free cortisol (UFC) levels in 15 of 19 patients with Cushing’s disease (CD). The most common AEs were nausea, diarrhea, asthenia, and adrenal insufficiency (n=6 each). Here, we report the 31-month efficacy and safety results from LINC-2 extension.Methods: Patients receiving clinical benefit at week 22 could enter ...

ea0037ep805 | Pituitary: clinical | ECE2015

Pituitary apoplexy in GH-deficient adults treated with GH – a KIMS database retrospective study

Radian Serban , Jonsson Peter J , Camacho-Hubner Cecilia , Biller Beverly M K , Buchfelder Michael , AEkerblad Ann-Charlotte , Korbonits Marta

Background: Pituitary apoplexy (PitApo) has significant associated-morbidity and its management is not yet standardised.Aim: To describe prevalence and characteristics of PitApo patients in GH deficient (GHD) patients compared with two control populations.Patients and methods: Patients with ‘infarction-apoplexy’ GHD aetiology code were identified from Pfizer International Metabolic Database (KIMS). Baseline characteristic...

ea0049gp187 | Pituitary & endocrine Tumours | ECE2017

Pasireotide alone or in combination with cabergoline effectively controls urinary free cortisol levels: results from a prospective study in patients with Cushing’s disease (CAPACITY)

Pivonello Rosario , Kadioglu Pritam , Bex Marie , Devia Deyanira Gonzalez , Boguszewski Cesar , Yavuz Dilek Gogas , Patino Heather , Campigotto Federico , Pedroncelli Alberto , Fleseriu Maria , Biller Beverly M K , Feelders Richard

Background: Pasireotide is a multireceptor-targeted somatostatin analogue that predominantly binds to somatostatin receptor subtype 5 (SSTR5) and provides sustained control of urinary free cortisol (UFC) levels in some patients with Cushing’s disease (CD). Cabergoline is a dopamine D2 receptor agonist with efficacy in some patients with CD. Most corticotropinomas co-express SSTR5 and D2, providing rationale for combination treatment with pasireotide and cabergoline. Resul...

ea0056gp205 | Pituitary Clinical | ECE2018

Predictors of response to long-acting pasireotide in patients with Cushing’s disease during a Phase III study

Witek Przemyslaw , Biller Beverly M K , Lacroix Andre , Feelders Richard , Li Yiming , Geer Eliza B , Brue Thierry , Ravichandran Shoba , Tauchmanova Libuse , Roughton Michael , Petersenn Stephan

Introduction: Long-acting pasireotide reduced urinary free cortisol (UFC) in most patients with Cushing’s disease (CD) during a large Phase III study (Lacroix et al. Lancet Diabetes Endocrinol 2018). The analyses presented here explored the impact of baseline characteristics on response to long-acting pasireotide.Methods: 150 patients with persistent, recurrent or de novo CD and mean UFC (mUFC; from three 24-hour samples collected ...

ea0041ep887 | Pituitary - Clinical | ECE2016

Long-term (19-month) control of urinary free cortisol with osilodrostat in patients with Cushing’s disease: results from an extension to the LINC-2 study

Pivonello Rosario , Hatipoglu Betul , Bertagna Xavier , Fleseriu Maria , Molitch Mark E , Shimizu Chikara , Tanaka Tomoaki , Shimatsu Akira , Biller Beverly M K , Ravichandran Shoba , Kandra Albert , Sauter Nicholas , Young Jacques

Introduction: During the 22-week LINC-2 study, the potent oral 11β-hydroxylase inhibitor osilodrostat normalized UFC in 15/19 (78.9%) patients with Cushing’s disease. Most common AEs were nausea, diarrhoea, asthenia, and adrenal insufficiency. This report describes 19-month results following an extension.Methods: Patients who were receiving clinical benefit at week 22 could enter the extension. Efficacy/safety is reported for patients who enter...

ea0070aep678 | Pituitary and Neuroendocrinology | ECE2020

Levoketoconazole in the treatment of endogenous Cushing’s syndrome: Extended evaluation phase results of the SONICS study

Fleseriu Maria , Auchus Richard J , Greenman Yona , Zacharieva Sabina , Geer Eliza B , Salvatori Roberto , Pivonello Rosario , Feldt-Rasmussen Ulla , Kennedy Laurence , Buchfelder Michael , Biller Beverly M K , Cohen Fredric , Heaney Anthony P

Background: The phase 3, open-label SONICS study of levoketoconazole demonstrated sustained reduction in mean urinary free cortisol (mUFC) in adults with endogenous Cushing’s syndrome (CS). The extended evaluation phase (Ext) of SONICS reported here further assessed long-term safety, tolerability, and benefit/risk of this treatment.Methods: SONICS consisted of dose-titration (150 – 600 mg BID to attain maximally tolerated dose for mUFC normal...

ea0056gp204 | Pituitary Clinical | ECE2018

Long-term efficacy and safety of once-monthly pasireotide in patients with Cushing’s disease: A Phase III extension study

Fleseriu Maria , Petersenn Stephan , Biller Beverly M K , Kadioglu Pinar , De Block Christophe , T'Sjoen Guy , Vantyghem Marie C , Tauchmanova Libuse , Ravichandran Shoba , Roughton Michael , Lacroix Andre , Newell-Price John

Introduction: The 12-month results of a multicentre, double-blind, Phase III study showing the efficacy and safety of a monthly, long-acting formulation of pasireotide in Cushing’s disease (CD) patients have been reported previously (Lacroix et al. Lancet Diabetes Endocrinol 2018). The results of the extension phase of this study are reported here.Methods: Patients (n=150) with persistent/recurrent or de novo CD and mean u...